Specialty pharmacy workflows—access, education, interaction checks, toxicity management—mitigate BTK antiplatelet risks and ...

Weekly cataplexy rates fell ~79%–89% with oveporexton versus ~28%–39% with placebo, increasing cataplexy-free days from 0 to ~3.8–5.1 weekly. Treatment-emergent adverse events were common (86%–89% vs ...

In "Evaluating Suspected LEMS: Differential Diagnosis and Palliative Care's Role," the panel examines how to evaluate a patient once LEMS enters the differential.

Dr. Patel defines LEMS as a neuromuscular disorder in which the synapses between nerve and muscle stop firing properly.

Before defining a network meta-analysis, Dr. Citrome walks through the statistical fundamentals that make one useful. He ...

The discussion opens with a foundational question: how does limited-stage small cell lung cancer differ from extensive-stage ...

Comprehensive upfront biomarker testing, including RAS, BRAF, HER2, and MSI status, now anchors first-line treatment selection in metastatic colorectal cancer, though reflexive testing adoption still ...

The “Washington Ways Without Means” session was moderated by Nick Ferreyros, managing director of policy, advocacy, and ...

Adoption data show a want–execution gap: AI use/experimentation exceeds 80%, but only 19% report deployed solutions, with cost, cybersecurity, and workflow disruption as leading barriers. The 2026 COA ...

Population Health, Equity & Outcomes is a quarterly publication dedicated to providing a platform for the exchange of research, policy analysis, and insights that aim to improve health outcomes and ...

Novel combinations may improve survival in Richter transformation, a hard-to-treat condition, says Adam Kittai, MD, of Perlmutter Cancer Center.

Mayo Clinic's Scott Soefje, PharmD, MBA, explains how logistics, contracts, and cost shape access to new cancer drugs and ...